{"entity":{"id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","aka":["HARMONi-GI3"],"tldr":"A phase 3 trial of CAPOX, FLOT in colorectal cancer, run by Summit Therapeutics, now recruiting.","summary":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07228832 by Summit Therapeutics, with 600 participants planned, started 2025-11-18 and due to reach its primary completion in 2028-05-31. Interventions recorded: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection. Conditions listed: Metastatic Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07228832","url":"https://clinicaltrials.gov/study/NCT07228832"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["capox","flot"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07228832","phase":"3","setting":"A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer","sponsor":"Summit Therapeutics","participation":[{"nct":"NCT07228832","source":"https://clinicaltrials.gov/study/NCT07228832","fetchedAt":"2026-10-07T16:55:34.394Z","studySha256":"ff08127f738868b7e93a05cbe53aa33f8683c352121d5eebc5828547bb1899ad","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Summit Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":600,"enrolmentType":"ESTIMATED","siteCount":236,"recruitingSiteCount":236,"countries":["Belgium","Canada","China","Czechia","France","Germany","Hungary","Italy","Japan","Mexico","Poland","Puerto Rico","Spain","United Kingdom","United States"]}],"started":"2025-11-18","startedType":"actual","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07228832/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}]}}